AI Article Synopsis
- The study aimed to assess the importance of the periportal hyperintensity sign seen in gadobenate dimeglumine-enhanced MRI for predicting outcomes in patients with decompensated cirrhosis.
- Out of 199 cirrhotic patients, significant differences in the prevalence of the hyperintensity sign were found between compensated and decompensated groups, indicating a higher risk for death and further health complications in the latter.
- The presence of the periportal hyperintensity sign was identified as a strong predictor for mortality (hazard ratio of 23.677) and further decompensation (hazard ratio of 2.594) in patients with decompensated cirrhosis.
Article Abstract
Objectives: To determine the value of periportal hyperintensity sign from gadobenate dimeglumine (Gd-BOPTA)-enhanced hepatobiliary phase (HBP) magnetic resonance imaging (MRI) for predicting clinical outcomes in patients with decompensated cirrhosis.
Methods: A total of 199 cirrhotic patients who underwent Gd-BOPTA-enhanced MRI were divided into control group (n = 56) and decompensated cirrhosis group (n = 143). The presence of periportal hyperintensity sign on HBP MRI was recorded. The Cox regression model was used to investigate the association between periportal hyperintensity sign and clinical outcomes.
Results: There was a significant difference in the frequency of periportal hyperintensity sign on HBP between compensated and decompensated cirrhotic patients (p < 0.05). After a median follow-up of 29.0 months (range, 1.0-90.0 months), nine out of 143 patients (6.2%) with decompensated cirrhosis died. Periportal hyperintensity sign on HBP MRI was a significant risk factor for death (hazard ratio (HR) = 23.677; 95% confidence interval (CI) = 4.759-117.788; p = 0.0001), with an area under the curve (AUC) of 0.844 (95% CI = 0.774-0.899). Thirty patients (20.9%) developed further decompensation. Periportal hyperintensity sign on HBP MRI was also a significant risk factor for further decompensation (HR = 2.594; 95% CI = 1.140-5.903; p = 0.023).
Conclusions: Periportal hyperintensity sign from Gd-BOPTA-enhanced HBP MRI is valuable for predicting clinical outcomes in patients with decompensated cirrhosis.
Critical Relevance Statement: Periportal hyperintensity sign from gadobenate dimeglumine-enhanced hepatobiliary phase magnetic resonance imaging is a new noninvasive method to predict clinical outcomes in patients with decompensated cirrhosis.
Key Points: • There was a significant difference in the frequency of periportal hyperintensity sign on HBP between compensated and decompensated cirrhotic patients. • Periportal hyperintensity sign on the hepatobiliary phase was a significant risk factor for death in patients with decompensated cirrhosis. • Periportal hyperintensity sign on the hepatobiliary phase was a significant risk factor for further decompensation in patients with decompensated cirrhosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10899122 | PMC |
| http://dx.doi.org/10.1186/s13244-024-01629-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A case report: mucinous carcinoma of extrahepatic bile ducts with periportal calcification suggestive of lymphatic calcification.
Abdom Radiol (NY)
October 2024
Kanazawa University, Kanazawa, Japan.
Article Synopsis
- * The patient's imaging tests revealed extensive periportal calcifications and hyperintense masses in the bile duct and lymph nodes, suggesting tumor presence and possible metastasis.
- * An endoscopic biopsy confirmed the diagnosis of mucinous carcinoma, which was associated with lymphatic vessel involvement and multiple lymph node metastases, with calcification thought to relate to the tumor's mucin production.
Magnetic resonance imaging features of progressive familial intrahepatic cholestasis type 3.
Radiologie (Heidelb)
November 2024
Department of Medical Imaging (Radiology), the Affiliated Hospital of Hangzhou Normal University, Zhejiang, China.
Purpose: Progressive familial intrahepatic cholestasis type 3 (PFIC-3) is a rare autosomal recessive cholestatic liver disorder. This study aimed to present the clinical and magnetic resonance imaging (MRI) features of three patients with PFIC‑3.
Methods: The study included three patients with cholestasis and pathogenic variants in the ABCB4 gene identified by next-generation sequencing of a targeted-gene panel or by whole-exome sequencing.
Correction: The value of periportal hyperintensity sign from gadobenate dimeglumine-enhanced hepatobiliary phase MRI for predicting clinical outcomes in patients with decompensated cirrhosis.
Insights Imaging
May 2024
Department of Health Management Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
The value of periportal hyperintensity sign from gadobenate dimeglumine-enhanced hepatobiliary phase MRI for predicting clinical outcomes in patients with decompensated cirrhosis.
Insights Imaging
February 2024
Department of Health Management Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, 250021, China.
Article Synopsis
- The study aimed to assess the importance of the periportal hyperintensity sign seen in gadobenate dimeglumine-enhanced MRI for predicting outcomes in patients with decompensated cirrhosis.
- Out of 199 cirrhotic patients, significant differences in the prevalence of the hyperintensity sign were found between compensated and decompensated groups, indicating a higher risk for death and further health complications in the latter.
- The presence of the periportal hyperintensity sign was identified as a strong predictor for mortality (hazard ratio of 23.677) and further decompensation (hazard ratio of 2.594) in patients with decompensated cirrhosis.
T2-weighted imaging and dynamic contrast‑enhanced imaging in predicting the prognosis in patients with acute-on-chronic liver failure.
BMC Gastroenterol
August 2023
Department of Radiology, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshun East Street, Chaoyang District, Beijing, China.
Background: Acute-on-chronic liver failure (ACLF) is a syndrome with high 28- and 90-day mortality rates. Magnetic resonance imaging (MRI) has been widely used to diagnose and evaluate liver disease. Our purpose is to determine the value of the imaging features derived from Gd-DTPA-enhanced MRI for predicting the poor outcome of patients with ACLF and develop a clinically practical radiological score.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!